Cargando…

Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach

BACKGROUND: Completely resected stage IIIA(N2) non-small cell lung cancer (NSCLC) comprises a heterogeneous population according to discrepancies in survival prognosis. Accumulating evidence suggests that tumor-infiltrating lymphocytes (TILs) are clinically significant, despite a lack of consensus r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Wen, Li, Yuan, Shen, Lei, Zhang, Qin, Cai, Xu-Wei, Zhu, Zheng-Fei, Sun, Meng-Hong, Chen, Hai-Quan, Fu, Xiao-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804351/ https://www.ncbi.nlm.nih.gov/pubmed/33488784 http://dx.doi.org/10.1177/1758835920984975

Ejemplares similares

Corrigendum to “Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunoscore approach”
Publicado: (2021)

Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
por: Feng, Wen, et al.
Publicado: (2016)

Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer
por: Zhang, Qin, et al.
Publicado: (2020)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

Postoperative radiotherapy for patients with completely resected stage IIIA‐N2 non‐small cell lung cancer: opt‐in or opt‐out
por: Zhu, Lucheng, et al.
Publicado: (2022)

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis
por: Zhu, Ying, et al.
Publicado: (2019)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer
por: Chen, Chih-Yu, et al.
Publicado: (2020)

The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume
por: Feng, Wen, et al.
Publicado: (2015)

Prognostic value of a modified Immunoscore in patients with stage I−III resectable colon cancer
por: Zhao, Ke, et al.
Publicado: (2021)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer
por: Berman, Abigail T, et al.
Publicado: (2013)

Therapeutic Strategies for Resectable Stage-IIIA N2 Non–Small Cell Lung Cancer Patients: A Network Meta-Analysis
por: Shen, Ziyang, et al.
Publicado: (2022)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
por: Boscolo, Alice, et al.
Publicado: (2020)

Early postoperative radiotherapy is associated with improved outcomes over late postoperative radiotherapy in the management of completely resected (R0) Stage IIIA-N2 non-small cell lung cancer
por: Wang, Huan-Huan, et al.
Publicado: (2017)

Postoperative Radiotherapy for Patients with Completely Resected Pathological Stage IIIA-N2 Non-small Cell Lung Cancer: A Preferential Benefit for Squamous Cell Carcinoma
por: Tian, Cuimeng, et al.
Publicado: (2020)

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy
por: Hui, Zhouguang, et al.
Publicado: (2015)

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
por: Fu, Sha, et al.
Publicado: (2015)

The Prognostic Significance of Multiple Station N2 in Patients with Surgically Resected Stage IIIA N2 Non-small Cell Lung Cancer
por: Lee, Jin Gu, et al.
Publicado: (2008)

Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
por: Qiao, Rong, et al.
Publicado: (2019)

Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
por: Zhao, Zihuan, et al.
Publicado: (2020)

Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Corrigendum: Correlation analysis of MRD positivity in patients with completely resected stage I-IIIA non-small cell lung cancer: a cohort study
por: Dong, Daling, et al.
Publicado: (2023)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Immunoscore(®) as a predictor of response to chemotherapy in stage II and stage III colon cancer
por: Mlecnik, Bernhard, et al.
Publicado: (2015)

Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer
por: Montemuiño Muñiz, Sara, et al.
Publicado: (2021)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
por: Wang, Jiangfeng, et al.
Publicado: (2021)

Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer
por: Shen, Qian, et al.
Publicado: (2023)

The prognosis of clinical stage IIIa non‐small cell lung cancer in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2023)

Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma
por: Li, Yanyan, et al.
Publicado: (2020)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
por: Sinicrope, Frank A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k4gra56bqq8htmdgqhet2adnp4